Health

U.S. FDA Approves Third Indication of Nubeqa (darolutamide) for Patients with Advanced Prostate cancer

DailyTrendDailyTrend
Jun 5, 2025 - 07:00
 0  0
U.S. FDA Approves Third Indication of Nubeqa (darolutamide) for Patients with Advanced Prostate cancer
Berlin, June 3, 2025 – Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for use in...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

FDA Approves Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the Treatment of Fibromyalgia

FDA Approves Tonmya (cyclobenzaprine hydrochloride subl...

DailyTrend Aug 16, 2025  0  0

Why Wildfire Fighters Are Getting Dangerously Sick

Why Wildfire Fighters Are Getting Dangerously Sick

DailyTrend Aug 17, 2025  0  0

B. Braun Medical Issues Voluntary Nationwide Recall of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL Due to the Presence of Particulate Matter

B. Braun Medical Issues Voluntary Nationwide Recall of ...

DailyTrend Aug 20, 2025  0  0

A 1990 Measles Outbreak Shows How the Disease Can Roar Back

A 1990 Measles Outbreak Shows How the Disease Can Roar ...

DailyTrend Aug 21, 2025  0  0

Trump’s Get-Tough Approach on Homelessness May Sweep Up Veterans

Trump’s Get-Tough Approach on Homelessness May Sweep Up...

DailyTrend Aug 19, 2025  0  0

Was Head-Binding an Ancient Way to Get Ahead?

DailyTrend Aug 22, 2025  0  0